NervGen to Host Inaugural R&D Day on September 30, 2026

R&D Day to feature an in-depth review of NVG-291, including its nonclinical and translational foundation, broader therapeutic potential, clinical data generated to date, perspectives from the SCI community, and the Phase 3 RESTORE study design and rationale Four leading experts spanning spinal cord injury clinical care, outcome assessment, translational research and community advocacy to join […]